Have a personal or library account? Click to login
Effects of coenzyme Q10 in a propofol infusion syndrome model of rabbits Cover

Effects of coenzyme Q10 in a propofol infusion syndrome model of rabbits

Open Access
|Oct 2023

Figures & Tables

Figure 1.

BIS monitoring in the rabbit.
BIS monitoring in the rabbit.

Figure 2.

General view of the experimental area.
General view of the experimental area.

Figure 3.

Light micrographs of the liver, gall bladder, kidney, and urinary bladder after the propofol or sevoflurane exposure with respect to saline or additional CoQ10 therapy (hematoxylin and eosin; 200×). The propofol and sevoflurane organ toxicities were recovered up to different extents with CoQ10 therapy. The desquamated mucosal epithelia recovered in the gall bladder and the urinary bladder with CoQ10 (the second and fourth column light micrographs). The portal inflammation, hepatocytic vacuolation, sinusoidal congestion, and dilatation partially improved with CoQ10 treatment (the first column). The kidney damage, which consisted of mainly vascular congestion and tubular injury, did not change much with the CoQ10 treatment (third column). C, vascular congestion; CoQ10, coenzyme Q10; D, dilatation; E, epithelium; I, inflammation; TI, tubular injury.
Light micrographs of the liver, gall bladder, kidney, and urinary bladder after the propofol or sevoflurane exposure with respect to saline or additional CoQ10 therapy (hematoxylin and eosin; 200×). The propofol and sevoflurane organ toxicities were recovered up to different extents with CoQ10 therapy. The desquamated mucosal epithelia recovered in the gall bladder and the urinary bladder with CoQ10 (the second and fourth column light micrographs). The portal inflammation, hepatocytic vacuolation, sinusoidal congestion, and dilatation partially improved with CoQ10 treatment (the first column). The kidney damage, which consisted of mainly vascular congestion and tubular injury, did not change much with the CoQ10 treatment (third column). C, vascular congestion; CoQ10, coenzyme Q10; D, dilatation; E, epithelium; I, inflammation; TI, tubular injury.

Figure 4.

Light micrographs of the spleen, lung, pancreas, and striated muscle (the heart) inset after the propofol or sevoflurane exposure with respect to saline or additional CoQ10 therapy (hematoxylin and eosin; 200×).
Light micrographs of the spleen, lung, pancreas, and striated muscle (the heart) inset after the propofol or sevoflurane exposure with respect to saline or additional CoQ10 therapy (hematoxylin and eosin; 200×).

The amount of total fluids and drugs given intravenously, serum CoQ10 levels and the time to death, and survival ratio at the 24th hour after the start of propofol infusion or sevofurane inhalation

PropofolPropofol + CoQ10SevofluraneSevoflurane + CoQ10P value
Total fluid given (mL)341 (225–875)186 (100–300)284 (200–390)170 (155–200)0.057
Total urine output (mL)160 (85–650)40 (20–100)150 (50–170)85 (50–100)0.073
Total bicarbonate5 (0–50)0 (0–10)0 (0–10)0 (0–0)0.424
Total propofol (mg)1400 (980–2200)1050 (760–2000)0 (0–0)0 (0–0)NA
Serum CoQ10 level (μg/mL) – basal0.14 (0.09–0.39)0.1 (0.06–0.23)0.26 (0.16–0.56)0.13 (0.05–0.21)0.131
Serum CoQ10 level (μg/mL) – 12th hour0.41 (0.38–0.45)0.23 (0.12–0.36)0.28 (0.08–0.58)0.16 (0.09–0.25)0.356
Serum CoQ10 level (μg/mL) – 24th hourN = 00.38 (N = 1)0.24 (N = 1)0.23 (0.11–0.34)NA
Time to death (h)12 (6–20)18 (16–24)20 (17–24)23 (20–24)0.066
Survival ratio (%) – 24th hour0 (0)1 (25)1 (25)2 (50)0.446

The laboratory results of the four experimental groups

PropofolPropofol + CoQ10SevofluraneSevoflurane + CoQ10P value
PH – basal7.37 (7.17–7.64)7.4 (7.19–7.55)7.43 (7.17–7.64)7.35 (7.25–7.5)0.980
pH – 12th hour7.40 (7.15–7.47)7.15 (7.15–7.15)7.37 (7.28–7.47)7.4 (7.28–7.46)0.804
PaCO2 – basal (mmHg)44.5 (14–63)42 (41–48)53.5 (14–61)30 (22–47)0.481
PaCO2 – 12th hour (mmHg)26 (20–38)34 (34–34)25 (24–26)27 (20–38)0.595
PaO2 – basal (mmHg)249 (149–371)258 (214–266)256 (149–316)217 (208–251)0.752
PaO2 – 12th hour (mmHg)240 (56–391)116 (116–116)301.5 (228–375)273 (185–380)0.508
Ca+2 – basal (mmol/L)1.3 (1–1.75)1.5 (1.52–1.75)1.42 (1–1.69)1.27 (1.07–1.35)0.237
Ca+2 – 12th hour (mmol/L)1.45 (0.4–1.61)0.4 (0.4–0.4)1.34 (1.24–1.45)1.5 (0.57–1.51)0.258
Glucose – basal (mg/dL)299 (135–467)307 (268–308)294 (226–463)320 (135–467)0.938
Glucose – 12th hour (mg/dL)111 (47–234)47 (47–47)93.5 (76–111)144 (121–234)0.162
Lactate – basal (mmol/L)2.85 (1–10.5)4 (1.2–10.5)1.4 (1–3.2)4.3 (3.9–5.2)0.190
Lactate – 12th hour (mmol/L)5 (3.1–8.8)4.3 (4.3–4.3)4.05 (3.1–5)5.3 (3.2–8.8)0.855
HCO3 – basal (mmol/L)26 (9.6–36.4)26 (18.3–36)28 (15.1–34.7)23.4 (9.6–25.9)0.548
HCO3 – 12th hour (mmol/L)16.7 (11.8–19.5)11.8 (11.8–11.8)16 (14.8–17.2)16.7 (14.2–17.9)0.277
BE – basal (mmol/L)0.35 (−17.6 to 13.5)1.2 (−9.9 to 13.5)3.6 (−6.2 to 11.1)0.2 (−17.6 to 0.3)0.586
BE – 12th hour (mmol/L)−7.2 (−17.1 to 14.2)−17.1 (−17.1 to 17.1)−10.1 (−13 to 7.2)8.8 (−8.1 to 14.2)0.294
Hematocrit – basal (%)34 (30–38)41 (35–46)37 (35–48)37 (35–40)0.282
Hematocrit – 12th hour (%)34 (34–34)41 (38–45)29 (22–43)35 (33–42)0.141
ALT – basal (U/L)32 (26–141)59 (44–68)63 (33–163)95 (62–110)0.484
ALT – 12th hour (U/L)84 (29–254)86 (63–214)252 (37–440)112 (93–487)0.606
AST – basal (U/L)86 (10–518)38 (28–41)46 (25–108)53 (30–74)0.606
AST – 12th hour (U/L)202 (100–1166)106 (90–820)509 (107–1421)98 (89–627)0.409
GGT – basal (U/L)9 (7–21)12 (8–18)8 (6–21)12 (9–15)0.628
GGT – 12th hour (U/L)9 (4–16)10 (7–102)9 (7–16)16 (9–17)0.676
Creatinine – basal (mg/dL)1.08 (0.9–1.20)1.12 (1.1–1.16)1.01 (0.8–1.15)0.9 (0.9–1.02)0.204
Creatinine – 12th hour (mg/dL)1.6 (0.8–3)2.14 (1.35–4.33)1.2 (0.9–3.2)1.4 (1.2–2.14)0.631
LDH – basal (U/L)746 (688–900)932 (444–1540)689 (600–720)629 (362–1410)0.508
LDH – 12th hour (U/L)1356 (1287–2200)1654 (1500–1944)1891 (1748–2595)845 (814–877)0.078
CK – basal hour (U/L)1847 (902–2137)2922 (2545–3300)1683 (1436–2089)1724 (1305–2203)0.191
CK – 12th hour (U/L)3838 (2961–5876)3118 (2900–5402)4236 (3594–9921)11415 (6000–12769)0.117
Amylase – basal (U/L)289 (281–350)285 (246–356)286 (218–333)291 (231–310)0.820
Amylase – 12th hour (U/L)485 (440–625)371 (323–605)341 (291–510)449 (364–1084)0.289
Troponin T – basal (ng/mL)0.03 (0.01–0.8)0.005 (0–0.001)0.05 (0.01–0.18)0.01 (0–0.01)0.535
Troponin T – 12th hour (ng/mL)0.94 (0.2–3.5)0.005 (0–0.026)*#0.15 (0.13–0.2)*0.01 (0–0.01)*#0.007
Cholesterol – basal (mg/dL)49 (32–55)30 (27–57)47 (27–92)32 (29–82)0.795
Cholesterol – 12th hour (mg/dL)119 (64–134)119 (43–124)49 (24–81)48 (29–68)0.138
Triglicerides – basal (mg/dL)156 (62–201)168 (67–270)60 (43–84)92 (98–152)0.139
Triglicerides – 12th hour (mg/dL)993 (663–5460)1013 (213–1549)#106 (62–270)*325 (126–525)0.038

The histopathologic organ injury scores

PropofolPropofol + CoQ10SevofluraneSevoflurane + CoQ10P value
Lung
Pulmonary edema2.5 (2–3)2.5 (1–3)2.5 (2–3)2.5 (2–3)0.983
Parenchymal congestion3 (2–3)2.5 (2–3)2.5 (2–3)2.5 (2–3)0.870
Alveolar hemorrhage1 (1–2)1 (1–3)1 (1–2)1 (1–1)0.794
Inflammation2 (2–2)2 (1–3)2 (2–2)2 (2–2)1
Lung injury score8.5 (7–10)8.5 (5–10)8.5 (7–9)8 (7–9)0.926
Liver
Necrosis0.5 (0–1)0 (0–0)1 (0–1)0 (0–0)0.061
Hepatocellular injury2 (2–3)1 (1–2)2 (2–2)1 (1–2)0.028
Congestion2.5 (2–3)2 (1–2)2.5 (2–3)1 (1–2)0.038
Inflammation1.5 (1–2)1 (0–1)2 (1–2)0.5 (0–1)0.039
Vacuolar degeneration3 (2–3)1.5 (1–2)2 (2–3)2 (2–2)0.037
Liver injury score10 (7–11)5 (4–7)*#9 (7–11)4.5 (4–7)*#0.016
Spleen
Congestion1.5 (1–2)0.5 (0–1)1 (1–2)0.5 (0–1)0.075
Fibrosis0 (0–1)0 (0–0)0 (0–1)0 (0–0)0.543
Spleen injury score1.5 (1–3)0.5 (0–1)1 (1–3)0.5 (0–1)0.079
Kidney
Congestion1.5 (1–2)1 (1–1)1 (1–2)1 (1–2)0.475
Necrosis2 (1–3)1 (1–2)1.5 (1–3)2 (2–2)0.306
Kidney injury score3.5 (2–5)2 (2–3)2.5 (2–5)3 (3–4)0.257
Heart
Congestion1 (0–1)0 (0–1)0.5 (0–1)0 (0–1)0.454
Necrosis0 (0–0)0 (0–0)0 (0–0)0 (0–0)1
Inflammation0 (0–1)0 (0––0)0.5 (0–1)0 (0–0)0.238
Heart injury score1 (0–2)0 (0–1)1 (0–2)0 (0–0)0.177
Muscle
Congestion1 (0–1)0 (0–1)0.5 (0–1)0 (0–0)0.172
Necrosis0 (0–0)0 (0–0)0 (0–0)0 (0–0)1
Inflammation0 (0–1)0 (0–0)0 (0–0)0 (0–0)0.392
Muscle injury score1 (0–2)0 (0–1)0.5 (0–1)0 (0–0)0.146
Gall bladder
Congestion1 (0–1)1 (0–1)1 (1–2)1 (0–1)0.419
Necrosis2 (0–2)0.5 (0–1)2 (1–2)1 (0–1)0.023
DOI: https://doi.org/10.2478/abm-2023-0058 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 173 - 184
Published on: Oct 18, 2023
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2023 Banu Kilicaslan, Seda B Akinci, Fatma Saricaoglu, Savas O Yılbas, Burcu A Ozkaya, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.